The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Please provide your email address to receive an email when new articles are posted on . Digitoxin reduced risk for death or worsening heart failure vs. placebo in patients with heart failure with ...
New findings from the DIGIT-HF trial show low-dose digitoxin can reduce the risk for hospitalization and all-cause mortality in patients with symptomatic heart failure. The results, presented at the ...
Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to ...
MADRID -- Digitoxin added to guideline-directed medical therapy improved outcomes among patients with heart failure and reduced ejection fraction (HFrEF), the DIGIT-HF trial showed. The cardiac ...
MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...
Madrid, Spain – 29 August 2025: Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening heart failure (HF) among patients with advanced HF and a reduced ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results